Search This Blog

Thursday, January 19, 2023

Apexigen: New Phase 2 Data on Antibody at ASCO Gastrointestinal Cancers Meet

 Results demonstrate sotigalimab’s ability to turn immunologically “cold” tumors “hot” to increase anti-tumor immune responses for increased therapeutic effect in patients with esophageal/gastro-esophageal junction and rectal cancers-

 Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from Phase 2 multicenter clinical trials evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in two poster presentations at the ASCO Gastrointestinal Cancers Symposium, being held both virtually and in San Francisco, California from January 19-21, 2023.

https://finance.yahoo.com/news/apexigen-announces-phase-2-data-130000510.html

India's Sun Pharma acquires U.S.-based Concert for $576 m

 Sun Pharmaceutical Industries Limited , India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness.

The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data.

Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close. Shares of the Massachusetts-based biopharma were trading up 19.4% at $8.24 in early trading.

https://finance.yahoo.com/news/1-indias-sun-pharma-acquire-132434367.html

NeuroSense: Positive Final Results from Alzheimer's Biomarker Study

 

  • Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform

  • Phase 2 double-blind proof-of-concept clinical study expected to commence in H1 2023

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results.

https://finance.yahoo.com/news/neurosense-therapeutics-reports-positive-final-135200403.html

Amazon Fined for Worker Safety Violations in 3 States

 US federal workplace safety regulators fined Amazon.com Inc. more than $60,000 for putting warehouse employees at risk for lower back injuries and other musculoskeletal disorders.

The Occupational Safety and Health Administration discovered the violations last year during inspections of Amazon warehouses in Deltona, Florida; Waukegan, Illinois; and New Windsor, New York.

“Each of these inspections found work processes that were designed for speed but not safety, and they resulted in serious worker injuries,” said Assistant Secretary for Occupational Safety and Health Doug Parker. “While Amazon has developed impressive systems to make sure its customers’ orders are shipped efficiently and quickly, the company has failed to show the same level of commitment to protecting the safety and well-being of its workers.”

Similar investigations at other Amazon facilities in Aurora, Colorado; Nampa, Idaho; and Castleton-on-Hudson, New York, continue.

Amazon spokesperson Kelly Nantel said the company takes workplace safety seriously and reduced injury rates nearly 15% between 2019 and 2021.

“We strongly disagree with these allegations and intend to appeal,” she said in an emailed statement. “We’ve cooperated fully, and the government’s allegations don’t reflect the reality of safety at our sites.”

The fines amount to a slap on the wrist for an enterprise of Amazon’s size but still represent a ratcheting up of pressure on the company, which has pledged to reduce injury rates that are higher than its industry peers. In December, OSHA cited Amazon for 14 record-keeping violations during an ongoing probe of six facilities in Colorado, Florida, Idaho, Illinois and New York. The unrecorded incidents included injuries to wrists, knees, backs and shoulders that resulted in employees missing work, OSHA said.

CureVac upped to Buy from Neutral by UBS

 Target to $18 from $8

https://finviz.com/quote.ashx?t=CVAC&ty=c&ta=1&p=d

Teva cut to Hold from Buy by Jefferies

 Target to $12 from $10

https://finviz.com/quote.ashx?t=TEVA&ty=c&ta=1&p=d

Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Tech

 Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a

Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies

Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments

https://finance.yahoo.com/news/editas-medicine-shoreline-biosciences-enter-120000080.html